Psychedelics
The latest news about Psychedelics: headlines, AI summaries and the full story from every source.
- DEA Proposes Increased Production Quotas for Psychedelics to Support Medical Research
- FDA Holds Hearing on Psychedelics as Optimi Health Advances MDMA Trial for PTSD
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Shifts Focus to Compass Pathways
- Jupiter Neurosciences Licenses ALA-002 from PharmAla Biotech in $100M Deal
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Development
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion, Expanding Psychedelic Drug Portfolio
- AtaiBeckley Surges Following Eli Lilly's Acquisition Offer Worth Up to $3.8 Billion
- AtaiBeckley Surges on Eli Lilly Acquisition Worth Up to $3.8 Billion
- Eli Lilly Acquires Psychedelics Maker AtaiBeckley for $2.8 Billion
- Compass Pathways Reports Positive Phase 3 Data on COMP360 for Treatment-Resistant Depression
- PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal with Jupiter Neurosciences
- Eli Lilly Shares Drop on Foundayo's Weak Performance; FDA Issues Psychedelic Vouchers
- Trump's Executive Order May Accelerate Psychedelic Therapy Regulation
- Trump Signs Executive Order to Accelerate Psychedelic Research and Regulation
- Trump's Psychedelics Executive Order Advances Research but Cannabis Reform Stalls
- Trump Signs Executive Order to Expedite Psychedelic Research for PTSD Treatment